Headquartered in Port Jefferson, NY, Symbio is a client-focused global full-service Clinical Research Organization (CRO) with strong focus on dermatology and inflammatory diseases. We manage all CRO core services in-house and have our offices in the USA and Europe. We deliver excellent service and provide experienced qualified personnel to strategically manage all aspects of your clinical trials.
In November of 2023, NY-headquartered Symbio, LLC and CA-headquartered Dow Development Laboratories, LLC merged with Münster (Germany)-based Proinnovera. This merger created one of the world’s largest specialized dermatology-focused clinical research organization. In September of 2024, after a successful integration process, the group was renamed from Symbio Proinnovera to Symbio.
Symbio offers expertise in Proof-of-Concept, medical device and Phase 1 – Phase 4 clinical studies and has completed over 650+ clinical studies to date, both in the USA and in Europe.
Developing and maintaining excellent relationships with experienced clinical research sites are vital to the success of any study and every CRO. As a direct result of our site relationships, Symbio trials receive the special attention they deserve. We take great pride in the strong relationships we have established over the years. These relationships have provided us the ability to streamline recruitment, creating shorter enrollment timelines with a lower number of sites.
Our Leadership Team Makes the Difference
Alan Morgan, BSc, FCCA
Chief Executive Officer
“Committed to driving excellence for customers, team members, and broader stakeholders who help us deliver.”
Shanna Smith, BS
Chief Commercial Officer
“We have an amazing global operations team whose longevity and experience offer our clients consistent, excellent customer service in executing any protocol globally. I am proud of our team and how they navigate challenging situations which allows us to continually strive for excellence.”
Debra Dow, PharmD, MBA
Chief Operating Officer
“Clinical research is a huge group effort. Our Symbio staff understands that we are all in this together, we all want to be part of something successful and work hard to make that happen.”
Evyan Cord-Cruz, MD
Director, Global Medical Affairs
“The Global Medical Affairs group is always available to help ensure the safety of study subjects.”
Peter Bernthaler, PhD
Director, Business Development EU
“Building bridges, forging connections, and driving growth – that’s the essence of business development.”
Chad Troller, BS, CCRA
Director, Business Development US
“There have been tremendous advances in our industry attributable to harnessing the power of technology. But the single most important factor will always remain. People. We owe our success to our partnership with Sponsors, the best Investigators, and by employing the best at Symbio. People are what make the difference.”
Tom McGuire, BS
Chief Technology Officer
“Technology enables us to gather data, manage documents and communicate more quickly than ever before. The systems put in place to use these resources are key to greater efficiencies, but they must also be compliant with regulations.”